Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups

By MilliporeSigma | April 26, 2017

MilliporeSigma announced that the company will sponsor the startup program at LabCentral, a biotechnology incubator, in Cambridge, Massachusetts. LabCentral is a private, non-profit organization that provides entrepreneurs and innovative life-sciences startups with lab space and resources to nurture the next generation of biotech companies. It comprises approximately 125 scientists and entrepreneurs.

MilliporeSigma’s collaboration with LabCentral, like its ongoing Emerging Biotech grant program, gives biotech startups access to process development tools, education programs and training to support their success and strengthen the biotech community.

“Innovation is at the heart of the life science industry and startups play an important role in developing new and often life-changing, scientific discoveries,” said Udit Batra, member of the executive board, Merck KGaA, Darmstadt Germany and CEO, MilliporeSigma. “We are collaborating with LabCentral to be a resource for these emerging companies and to help them get the best start possible.”

As a sponsor of the LabCentral startup program, MilliporeSigma will “adopt” a startup company which entitles the selected company to a priority spot and one-year prepaid lab bench in LabCentral’s shared laboratory workspace. Candidates can consult program rules and submit their application at emdmillipore.com. Submission close is July 2, 2017.

“This is an exciting time at LabCentral as we begin construction on our facility expansion, which will make room for an additional 30 startups,” said Johannes Fruehauf, M.D., Ph.D., LabCentral co-founder and president. “Today, LabCentral has become the de facto standard in co-working facilities for biotech startups. From the breadth and quality of our infrastructure and equipment, to our supportive services and programming, to the LabCentral startup program—our sponsors are critical partners.”

The life science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 19,000 employees and 65 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.

(Source: MilliporeSigma)


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE